Dermata is a clinical-stage biotechnology company founded in late 2014 focused on the treatment of multiple medical and aesthetic skin conditions and diseases with high unmet needs. 

Our business strategy is to identify and develop innovative products that we can quickly move through clinical trials to demonstrate efficacy and safety in a variety of skin diseases.  We are currently exploring the use of a unique naturally derived technology with both mechanical and chemical mechanisms of action to treat skin diseases and aesthetic skin conditions while creating a shift in how these indications are treated.  With multiple dermatologic indications being investigated, such as acne, psoriasis and rosacea, we have begun to build a robust pipeline that will create significant value for our stockholders.  We believe this strategy will enable us to build a platform of products that we can efficiently move from R&D, through development and into commercialization with an attractive capital return.